NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Tiziana Life Sciences Ltd. TLSA
9 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
EPS · FY24
$-0.11
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2024 · full 9-year series below
Revenue
Net income
Per share
USD -0.11
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin—
Net margin—
Return on assets-101.1%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 11.3M
total assets, end of FY2024
Total assetsUSD 11.3M
CashUSD 3.7M
Current ratio1.02×
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
·
·
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
Income tax $B
−0.0
0.0
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.11
−0.17
−0.15
−0.24
−0.16
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
Shares out B
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
22 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 3 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed